Clinical Trials
374 trialsCombination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Kura Oncology, Inc.
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer
Ono Pharmaceutical Co., Ltd.
CLIO-1
Regeneron Pharmaceuticals
MK-2140-004
Merck Sharp & Dohme LLC
First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma
CEBIOTEX
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
PureTech
KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
DREAMM 14
GlaxoSmithKline
ZUMA-4
Gilead Sciences
A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
Otsuka Pharmaceutical Co., Ltd.
A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma
Shanghai Pharmaceuticals Holding Co., Ltd
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Janssen Research & Development, LLC
KarMMa-2
Celgene
ALPHA
Allogene Therapeutics
MagnetisMM-9
Pfizer
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Newave Pharmaceutical Inc
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Blueprint Medicines Corporation
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Acerta Pharma BV
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
Alpha Tau Medical LTD.
MK-1454-002
Merck Sharp & Dohme LLC
GuidePath
Novartis
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
Alexion Pharmaceuticals, Inc.
ELARA
Novartis
E7080-G000-231
Merck Sharp & Dohme LLC
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
Wugen, Inc.
Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Takeda
Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant
Astellas Pharma Inc
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Regeneron Pharmaceuticals
SELECT
Amgen
Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation
AstraZeneca
EXCYTE-2
Exscientia AI Limited
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Incyte Corporation
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Incyte Corporation
A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
FIGHT-210
Incyte Corporation
A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Novartis
Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab
Leap Therapeutics, Inc.
TRANSFORM
Celgene
A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Bristol-Myers Squibb
A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma
Wuhan YZY Biopharma Co., Ltd.
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy
PhytoHealth Corporation
CerebralEDV
Engeneic Pty Limited
A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation
Astellas Pharma Inc
DISCOVER
Biogen
KarMMa
Celgene
RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma
Rapa Therapeutics LLC
Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals